Evogene
EVGN
18 hedge funds and large institutions have $48.4M invested in Evogene in 2016 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 3 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
0.58% more ownership
Funds ownership: 28.84% → 29.43% (+0.58%)
14% less funds holding
Funds holding: 21 → 18 (-3)
15% less capital invested
Capital invested by funds: $56.8M → $48.4M (-$8.4M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$659K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$393K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$348K |
| 4 |
MCM
Moon Capital Management
New York
|
+$183K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$99.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Penserra Capital Management
Orinda,
California
|
-$7.35M |
| 2 |
MTWSIF
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
-$431K |
| 3 |
Citigroup
New York
|
-$157K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$10K |
| 5 |
Goldman Sachs
New York
|
-$5.78K |
EVGN Hedge Fund Activity: Q2 2016 in Review
18 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q2 2016, worth a combined $48.4M — down 15% from $56.8M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of EVGN and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Bank of America, adding an estimated $659K. The largest seller was Penserra Capital Management, exiting entirely with an estimated $7.35M sold.
- 18 institutional investors held Evogene (EVGN) as of Q2 2016, down from 21 in Q1 2016.
- Funds reported $48.4M of Evogene stock for Q2 2016, down 15% quarter-over-quarter.
- 0 funds opened new Evogene positions in Q2 2016 and 3 closed out, a net change of -3 holders.
- The largest Evogene buyer in Q2 2016 was Bank of America, an estimated $659K added.
- The largest Evogene seller in Q2 2016 was Penserra Capital Management, an estimated $7.35M sold.
Based on aggregated 13F filings for Q2 2016.